GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2) » Definitions » Future 3-5Y Total Revenue Growth Rate

BioLine Rx (STU:YP2) Future 3-5Y Total Revenue Growth Rate : N/A (As of May. 28, 2025)


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, BioLine Rx's Future 3-5Y Total Revenue Growth Rate is N/A.


Competitive Comparison of BioLine Rx's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, BioLine Rx's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

BioLine Rx  (STU:YP2) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


BioLine Rx Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2) » Definitions » Future 3-5Y Total Revenue Growth Rate
Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx Headlines

No Headlines